Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06764875




Registration number
NCT06764875
Ethics application status
Date submitted
12/12/2024
Date registered
9/01/2025
Date last updated
9/01/2025

Titles & IDs
Public title
A Phase ? Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Scientific title
A Randomized, Phase ? Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)
Secondary ID [1] 0 0
2024-512583-57-00
Secondary ID [2] 0 0
D702AC00001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
HER2-positive Gastric Cancer 0 0
Gastroesophageal Junction Adenocarcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Stomach

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Rilvegostomig
Treatment: Drugs - Trastuzumab deruxtecan
Treatment: Drugs - Trastuzumab
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - 5-fluorouracil
Treatment: Drugs - Capecitabine
Treatment: Drugs - Cisplatin
Treatment: Drugs - Oxaliplatin

Experimental: Arm A - T-DXd + Rilvegostomig + Fluoropyrimidine (Capecitabine OR 5-FU)

Active comparator: Arm B - Pembrolizumab + Trastuzumab + FP (5-FU plus cisplatin) or CAPOX (capecitabine plus oxaliplatin)

Active comparator: Arm C - Rilvegostomig + Trastuzumab + FP (5-FU plus cisplatin) or CAPOX (capecitabine plus oxaliplatin)


Treatment: Drugs: Rilvegostomig
Q3W, intravenous infusion

Treatment: Drugs: Trastuzumab deruxtecan
Q3W, intravenous infusion

Treatment: Drugs: Trastuzumab
Q3W, intravenous infusion

Treatment: Drugs: Pembrolizumab
Q3W, intravenous infusion

Treatment: Drugs: 5-fluorouracil
Q3W, intravenous infusion

Treatment: Drugs: Capecitabine
BID, oral administration

Treatment: Drugs: Cisplatin
Q3W, intravenous infusion

Treatment: Drugs: Oxaliplatin
Q3W, intravenous infusion
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression free survival (PFS)
Timepoint [1] 0 0
Up to approximately 6 years
Primary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
Up to approximately 6 years
Secondary outcome [1] 0 0
Objective Response Rate (ORR)
Timepoint [1] 0 0
Up to approximately 6 years
Secondary outcome [2] 0 0
Duration of Response (DoR)
Timepoint [2] 0 0
Up to approximately 6 years
Secondary outcome [3] 0 0
Proportion of all randomized participants alive and progression-free at 6 months (PFS6)
Timepoint [3] 0 0
Up to 6 months
Secondary outcome [4] 0 0
Proportion of all randomized participants alive and progression-free at 12 months (PFS12)
Timepoint [4] 0 0
Up to 12 months
Secondary outcome [5] 0 0
Time to second progression or death (PFS2)
Timepoint [5] 0 0
Up to approximately 6 years
Secondary outcome [6] 0 0
Occurrence of adverse events (AEs) and serious adverse events (SAEs)
Timepoint [6] 0 0
Up to approximately 6 years
Secondary outcome [7] 0 0
Pharmacokinetics (PK) of rilvegostomig, T-DXd, total anti-HER2 antibody, DXd, 5-FU, and capecitabine in serum
Timepoint [7] 0 0
Up to approximately 6 years
Secondary outcome [8] 0 0
Immunogenicity of rilvegostomig and T-DXd assessed by the presence of antidrug antibodies (ADAs) for rilvegostomig and T-DXd
Timepoint [8] 0 0
Up to approximately 6 years
Secondary outcome [9] 0 0
Increase in enteral feeding assistance and eating difficulties
Timepoint [9] 0 0
Up to approximately 6 years
Secondary outcome [10] 0 0
Proportion of time on study intervention with high side-effect bother
Timepoint [10] 0 0
Up to approximately 6 years
Secondary outcome [11] 0 0
Overall Survival at 12 months (OS12)
Timepoint [11] 0 0
Up to 12 months
Secondary outcome [12] 0 0
Overall Survival at 24 months (OS24)
Timepoint [12] 0 0
Up to 24 months
Secondary outcome [13] 0 0
Pharmacokinetics (PK) of rilvegostomig, T-DXd, total anti-HER2 antibody, DXd, 5-FU, and capecitabine in serum
Timepoint [13] 0 0
Up to approximately 6 years

Eligibility
Key inclusion criteria
* HER2 positive for gastric cancer on a tumor biopsy.
* PD-L1 combined positive score (CPS) = 1.
* Provision of tumor tissue sample from recent biopsy adequate for HER2 and PD-L1 testing.
* Previously untreated, unresectable, locally advanced or metastatic gastric or GEJ adenocarcinoma.
* WHO or Eastern Cooperative Oncology Group performance status of 0 or 1.
* Have measurable target disease assessed by the Investigator based on RECIST v1.1.
* Have adequate organ and bone marrow function within 14 days before randomization.
* LVEF = 55% within 28 days before randomization.
* Adequate treatment washout period before randomization.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Lack of physiological integrity of the upper gastrointestinal tract.
* Known dihydropyrimidine dehydrogenase enzyme deficiency.
* Contraindication to pembrolizumab or trastuzumab, contraindications to fluoropyrimidine (5-FU and capecitabine) or platinum (cisplatin and oxaliplatin) treatment as per local label.
* History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence.
* Persistent toxicities caused by previous anti-cancer therapy.
* Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring corticosteroid or anticonvulsant may be included in the study if they have recovered from the acute toxic effect of radiotherapy.
* Uncontrolled infection including tuberculosis and active hepatitis A infection.
* Uncontrolled infection requiring intravenous (IV) antibiotics, anti-virals, or antifungals.
* Recent receipt of live, attenuated vaccine.
* Chronic/active HBV or HCV infection unless controlled.
* Clinically significant cardiac or psychological conditions.
* Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.
* History of (non-infectious) ILD/pneumonitis, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
* Lung-specific intercurrent clinically significant illnesses.
* Any active non-infectious skin disease requiring systemic treatment.
* A pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or cell-free and concentrated ascites reinfusion therapy (CART).
* History of any of the following: drug-induced severe cutaneous adverse reaction.
* Any concurrent antic-ancer treatment with the exception of receptor activator of nuclear factor kappa-B ligand inhibitors.
* Have had major surgical procedure recently (excluding placement of vascular access) or recent significant traumatic injury or an anticipated need for major surgery during the study.
* Current or prior use of immunosuppressive medication within 14 days before study intervention.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
28/03/2025
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
9/12/2030
Actual
Sample size
Target
840
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Westmead
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
Tennessee
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Virginia
Country [14] 0 0
Austria
State/province [14] 0 0
Linz
Country [15] 0 0
Austria
State/province [15] 0 0
Salzburg
Country [16] 0 0
Austria
State/province [16] 0 0
Wiener Neustadt
Country [17] 0 0
Austria
State/province [17] 0 0
Wien
Country [18] 0 0
Belgium
State/province [18] 0 0
Edegem
Country [19] 0 0
Belgium
State/province [19] 0 0
Gent
Country [20] 0 0
Belgium
State/province [20] 0 0
Leuven
Country [21] 0 0
Brazil
State/province [21] 0 0
Barretos
Country [22] 0 0
Brazil
State/province [22] 0 0
Brasilia
Country [23] 0 0
Brazil
State/province [23] 0 0
Campo Grande
Country [24] 0 0
Brazil
State/province [24] 0 0
Natal
Country [25] 0 0
Brazil
State/province [25] 0 0
Porto Alegre
Country [26] 0 0
Brazil
State/province [26] 0 0
Recife
Country [27] 0 0
Brazil
State/province [27] 0 0
Salvador
Country [28] 0 0
Brazil
State/province [28] 0 0
Sao Paulo
Country [29] 0 0
Brazil
State/province [29] 0 0
Vitória
Country [30] 0 0
Canada
State/province [30] 0 0
Alberta
Country [31] 0 0
Canada
State/province [31] 0 0
Ontario
Country [32] 0 0
Canada
State/province [32] 0 0
Quebec
Country [33] 0 0
China
State/province [33] 0 0
Anyang
Country [34] 0 0
China
State/province [34] 0 0
Beijing
Country [35] 0 0
China
State/province [35] 0 0
Bengbu
Country [36] 0 0
China
State/province [36] 0 0
Changchun
Country [37] 0 0
China
State/province [37] 0 0
Changsha
Country [38] 0 0
China
State/province [38] 0 0
Chengdu
Country [39] 0 0
China
State/province [39] 0 0
Fuzhou
Country [40] 0 0
China
State/province [40] 0 0
Guangzhou
Country [41] 0 0
China
State/province [41] 0 0
Hangzhou
Country [42] 0 0
China
State/province [42] 0 0
Harbin
Country [43] 0 0
China
State/province [43] 0 0
Hefei
Country [44] 0 0
China
State/province [44] 0 0
Jinan
Country [45] 0 0
China
State/province [45] 0 0
Kunming
Country [46] 0 0
China
State/province [46] 0 0
Lanzhou
Country [47] 0 0
China
State/province [47] 0 0
Linfen
Country [48] 0 0
China
State/province [48] 0 0
Linyi
Country [49] 0 0
China
State/province [49] 0 0
Nanchang
Country [50] 0 0
China
State/province [50] 0 0
Nanjing
Country [51] 0 0
China
State/province [51] 0 0
Shandong
Country [52] 0 0
China
State/province [52] 0 0
Shanghai
Country [53] 0 0
China
State/province [53] 0 0
Shenyang
Country [54] 0 0
China
State/province [54] 0 0
Shijiazhuang
Country [55] 0 0
China
State/province [55] 0 0
Tianjin
Country [56] 0 0
China
State/province [56] 0 0
Wenzhou
Country [57] 0 0
China
State/province [57] 0 0
Wuhan
Country [58] 0 0
China
State/province [58] 0 0
Xi'an
Country [59] 0 0
China
State/province [59] 0 0
Xian
Country [60] 0 0
China
State/province [60] 0 0
Xining
Country [61] 0 0
China
State/province [61] 0 0
Yinchuan
Country [62] 0 0
China
State/province [62] 0 0
Zhengzhou
Country [63] 0 0
France
State/province [63] 0 0
Bordeaux
Country [64] 0 0
France
State/province [64] 0 0
Caen Cedex 5
Country [65] 0 0
France
State/province [65] 0 0
Clermont-Ferrand
Country [66] 0 0
France
State/province [66] 0 0
Dijon
Country [67] 0 0
France
State/province [67] 0 0
Lyon
Country [68] 0 0
France
State/province [68] 0 0
Marseille
Country [69] 0 0
France
State/province [69] 0 0
Rennes
Country [70] 0 0
France
State/province [70] 0 0
Toulouse
Country [71] 0 0
France
State/province [71] 0 0
Villejuif Cedex
Country [72] 0 0
Germany
State/province [72] 0 0
Augsburg
Country [73] 0 0
Germany
State/province [73] 0 0
Bad Saarow
Country [74] 0 0
Germany
State/province [74] 0 0
Berlin
Country [75] 0 0
Germany
State/province [75] 0 0
Braunschweig
Country [76] 0 0
Germany
State/province [76] 0 0
Chemnitz
Country [77] 0 0
Germany
State/province [77] 0 0
Düsseldorf
Country [78] 0 0
Germany
State/province [78] 0 0
Essen
Country [79] 0 0
Germany
State/province [79] 0 0
Frankfurt
Country [80] 0 0
Germany
State/province [80] 0 0
Göttingen
Country [81] 0 0
Germany
State/province [81] 0 0
Hamburg
Country [82] 0 0
Germany
State/province [82] 0 0
Leipzig
Country [83] 0 0
Germany
State/province [83] 0 0
Ludwigshafen
Country [84] 0 0
Germany
State/province [84] 0 0
Mannheim
Country [85] 0 0
Germany
State/province [85] 0 0
Ulm
Country [86] 0 0
Hong Kong
State/province [86] 0 0
Hong Kong
Country [87] 0 0
Hungary
State/province [87] 0 0
Budapest
Country [88] 0 0
Hungary
State/province [88] 0 0
Gyula
Country [89] 0 0
Hungary
State/province [89] 0 0
Gyor
Country [90] 0 0
Hungary
State/province [90] 0 0
Zalaegerszeg
Country [91] 0 0
Italy
State/province [91] 0 0
Firenze
Country [92] 0 0
Italy
State/province [92] 0 0
Milano
Country [93] 0 0
Italy
State/province [93] 0 0
Padova
Country [94] 0 0
Italy
State/province [94] 0 0
Rozzano
Country [95] 0 0
Italy
State/province [95] 0 0
Tricase
Country [96] 0 0
Japan
State/province [96] 0 0
Shiwa-gun
Country [97] 0 0
Malaysia
State/province [97] 0 0
Ipoh
Country [98] 0 0
Malaysia
State/province [98] 0 0
Kuala Lumpur
Country [99] 0 0
Malaysia
State/province [99] 0 0
Sabah
Country [100] 0 0
Netherlands
State/province [100] 0 0
Arnhem
Country [101] 0 0
Spain
State/province [101] 0 0
Badalona
Country [102] 0 0
Spain
State/province [102] 0 0
Barcelona
Country [103] 0 0
Spain
State/province [103] 0 0
Madrid
Country [104] 0 0
Spain
State/province [104] 0 0
Orense
Country [105] 0 0
Spain
State/province [105] 0 0
Santander
Country [106] 0 0
Spain
State/province [106] 0 0
Sevilla
Country [107] 0 0
Spain
State/province [107] 0 0
Valencia
Country [108] 0 0
Taiwan
State/province [108] 0 0
Kaohsiung
Country [109] 0 0
Thailand
State/province [109] 0 0
Bangkok
Country [110] 0 0
Thailand
State/province [110] 0 0
Banphaeo
Country [111] 0 0
Thailand
State/province [111] 0 0
Dusit
Country [112] 0 0
Thailand
State/province [112] 0 0
Khon Kaen
Country [113] 0 0
Turkey
State/province [113] 0 0
Ankara
Country [114] 0 0
Turkey
State/province [114] 0 0
Antalya
Country [115] 0 0
Turkey
State/province [115] 0 0
Diyarbakir
Country [116] 0 0
Turkey
State/province [116] 0 0
Erzurum
Country [117] 0 0
Turkey
State/province [117] 0 0
Izmir
Country [118] 0 0
Turkey
State/province [118] 0 0
Mezitli
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Cambridge
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Coventry
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Dundee
Country [122] 0 0
United Kingdom
State/province [122] 0 0
London
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Manchester
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Sutton
Country [125] 0 0
Vietnam
State/province [125] 0 0
Hanoi
Country [126] 0 0
Vietnam
State/province [126] 0 0
Ho Chi Minh city
Country [127] 0 0
Vietnam
State/province [127] 0 0
Vinh

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase ?, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS = 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.
Trial website
https://clinicaltrials.gov/study/NCT06764875
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06764875